Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 1
1968 4
1971 1
1978 2
1979 1
1981 3
1982 2
1986 1
1988 2
1993 1
1998 1
1999 2
2000 4
2002 2
2004 1
2005 3
2006 3
2007 4
2008 4
2009 3
2010 3
2011 5
2012 2
2013 4
2014 5
2015 2
2016 3
2017 4
2018 6
2019 7
2020 13
2021 12
2022 10
2023 10
2024 24
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
Sosero YL, Bandres-Ciga S, Ferwerda B, Tocino MTP, Belloso DR, Gómez-Garre P, Faouzi J, Taba P, Pavelka L, Marques TM, Gomes CPC, Kolodkin A, May P, Milanowski LM, Wszolek ZK, Uitti RJ, Heutink P, van Hilten JJ, Simon DK, Eberly S, Alvarez I, Krohn L, Yu E, Freeman K, Rudakou U, Ruskey JA, Asayesh F, Menéndez-Gonzàlez M, Pastor P, Ross OA, Krüger R; NCER‐PD Consortium; Corvol JC, Koks S, Mir P, De Bie RMA, Iwaki H, Gan-Or Z; International Parkinson's Disease Genomic Consortium. Sosero YL, et al. Mov Disord. 2024 Oct;39(10):1773-1783. doi: 10.1002/mds.29960. Epub 2024 Aug 12. Mov Disord. 2024. PMID: 39132902
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.
Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F. Scafetta R, et al. Among authors: minelli m. Breast. 2025 Aug;82:104502. doi: 10.1016/j.breast.2025.104502. Epub 2025 May 15. Breast. 2025. PMID: 40424680 Free PMC article.
HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G, Biganzoli L, Pronzato P, Montemurro F, Dambrosio M, Minelli M, Molteni L, Scaltriti L. Mustacchi G, et al. Among authors: minelli m. Crit Rev Oncol Hematol. 2015 Jul;95(1):78-87. doi: 10.1016/j.critrevonc.2015.02.002. Epub 2015 Feb 20. Crit Rev Oncol Hematol. 2015. PMID: 25748080 Review.
Selective Clamping for Robot-Assisted Surgical Procedures.
Furnari G, Minelli M, Puliatti S, Micali S, Secchi C, Ferraguti F. Furnari G, et al. Among authors: minelli m. Annu Int Conf IEEE Eng Med Biol Soc. 2024 Jul;2024:1-7. doi: 10.1109/EMBC53108.2024.10782151. Annu Int Conf IEEE Eng Med Biol Soc. 2024. PMID: 40039535
Practice parameters for sublingual immunotherapy.
Ortolani C, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M, Cadario G, Campi P, Cardinale F, Ciprandi G, D'Anneo R, Di Gioacchino M, Di Rienzo V, Fiocchi A, Galimberti M, Galli E, Giovannini M, Incorvaia C, La Grutta S, Lombardi C, Marcucci F, Marseglia G, Minelli M, Musarra A, Nettis E, Novembre E, Pajno G, Patriarca G, Pezzuto F, Piras P, Pucci S, Romano A, Romano C, Quercia O, Scala G, Schiavino D, Senna G, Sforza G, Tosca M, Tripodi S, Frati F. Ortolani C, et al. Among authors: minelli m. Monaldi Arch Chest Dis. 2006 Mar;65(1):44-6. doi: 10.4081/monaldi.2006.586. Monaldi Arch Chest Dis. 2006. PMID: 16700194 Review.
158 results